Acute therapy for cluster headache with sumatriptan: Findings of a one-year long-term study

Göbel, Hartmut; Lindner, V.; Heinze, Axel; Ribbat, M.-J.; Deuschl, Günther

doi:10.1212/wnl.51.3.908

Cited by 115 publications

(86 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with CCH responded well to the use of subcutaneous sumatriptan, but to a lesser extent than ECH patients: 72.9% of ECH patients were pain free within 15 min compared to 60% of CCH patients [21]. Also, CCH patients responded more slowly than patients with ECH.…”

Section: Therapymentioning

confidence: 92%

Chronic cluster headache: a review

2005

View full text Add to dashboard Cite

Cluster headache (CH) is a rare but severe headache disorder characterised by repeated unilateral head pain attacks accompanied by ipsilateral autonomic features. In episodic CH, there are periods of headache attacks with pain–free intervals of weeks, months or years in between. A minority of patients have the chronic form, without pain–free intervals between the headache attacks. Chronic CH can occur as primary or secondary chronic CH; the rarest form is episodic CH arising from chronic CH. In this article, we give a review of the chronic forms of CH and focus on demographics, clinical manifestations, social habits, predictive factors, head injury, genetics, neuroimaging and therapy. It is remarkable that little is known about risk factors that make CH chronic.

show abstract

Section: Therapymentioning

confidence: 92%

Chronic cluster headache: a review

2005

View full text Add to dashboard Cite

show abstract

“…Adverse events were quantitatively similar to those seen in migraine trials and did not increase with frequent use of sumatriptan. In the second trial [51], investigators evaluated subcutaneous sumatriptan, administered over a period of up to 1 year, in a total of 2031 attacks in 52 patients. The drug proved highly effective in 88% of patients, with no evidence of tachyphylaxis or rebound headaches.…”

Section: Sumatriptanmentioning

confidence: 99%

Serotonergic Agents in the Management of Cluster Headache

Lambru

Matharu

2011

Curr Pain Headache Rep

View full text Add to dashboard Cite

Cluster headache is a highly disabling primary headache disorder, characterized by unilateral headache attacks occurring in association with cranial autonomic symptoms. Serotonergic agents, such as the ergot alkaloids, have traditionally been used for the acute and preventive treatment of cluster headache and other primary headaches. Although it initially was thought that their efficacy was due solely to the vasoconstriction of extracranial cerebral vessels, new mechanisms of action of these drugs have been ascertained as a consequence of advances in elucidation of the pathogenesis of primary headaches and the development of triptans. This article reviews the current knowledge about serotonergic agonists and antagonists used in the management of cluster headache, focusing on their mechanisms of action and on the possible role of serotonin system dysfunction in this complex disorder.

show abstract

“…In 2000, Centonze et al [11] noticed there were no cases of tachyphylaxis. However, Goebel et al in 1998 [12] noticed that for 13% of 52 patients, there was an increase in the number of daily attacks. Moreover, the drug was less effective for chronic cluster headache.…”

Section: Discussionmentioning

confidence: 97%

Does repeated subcutaneous administration of sumatriptan produce an unfavorable evolution in cluster headache?

et al. 2004

View full text Add to dashboard Cite

Cluster headache (CH) is one of the most painful primitive headaches that exists. Since 1991, the subcutaneous administration of sumatriptan (SCS) in the treatment of acute attacks has proved to be rapid and effective. Moreover, SCS has an excellent safety-efficacy ratio. To date, there is no information on the modalities of SCS use by CH patients, and on its possible overuse. In fact, some patients have noticed that the use of this drug on a regular basis modifies the evolution of attacks. We retrospectively studied, in 67 patients admitted for CH, the modalities of self-administering SCS the subjective feeling of medication overuse and its repercussions on attacks. A total of 47 patients used exclusively SCS as an acute treatment, 30 of whom had used more than two injections daily. Four patients whose use of SCS was the highest had also been drug addicts. Twenty-two patients using exclusively SCS thought that sumatriptan could have modified the evolution of attacks: 20 patients thought that the attacks occurred more frequently; 11 commented that the attacks became more intense, and the remaining 11 patients stated that sumatriptan had become less efficient. In CH, overuse of sumatriptan could aggravate the evolution of attacks. Further research is needed to corroborate this argument.

show abstract

Acute therapy for cluster headache with sumatriptan: Findings of a one-year long-term study

Cited by 115 publications

References 4 publications

Chronic cluster headache: a review

Chronic cluster headache: a review

Serotonergic Agents in the Management of Cluster Headache

Does repeated subcutaneous administration of sumatriptan produce an unfavorable evolution in cluster headache?

Contact Info

Product

Resources

About